Nuveen Churchill Direct Lending
NCDL · NYSE
About NCDL
- Employees
- 0
- Headquarters
- New York City, New York
- Listed
- Jan 25, 2024
- Sector
- Financials
- Industry
- Capital Markets
- Website
- churchillam.com
NCDL key statistics
- Market cap
- 516.09M
- Price-earnings ratio
- 9.28
- Dividend yield
- —
- Average volume
- 257.31K
- Volume
- 289.16K
- Open price
- $10.40
- High today
- $10.69
- Low today
- $10.39
- 52 Week high
- $15.07
- 52 Week low
- $10.31
Nuveen Churchill Direct Lending (NCDL) at a glance
Nuveen Churchill Direct Lending (NCDL) last traded at $10.45, with a market cap of 516.09M and a price-to-earnings ratio of 9.28.
Today the stock has traded between $10.39 and $10.69. The current price is 0.6% above the day's low and 2.2% below its high.
Volume so far is 289.16K shares, in line with the average of 257.31K shares a day.
Over the past year Nuveen Churchill Direct Lending has ranged from $10.31 to $15.07, and now sits 3% of the way up that range.
Nuveen Churchill Direct Lending met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported $0.41 per share against an estimate of $0.3978.
The average analyst price target is $14.36, 37.5% above the current price, from 5 recent ratings.
Analyst ratings
Latest rating from each analyst over the past 12 months
- Buy40.0%
- Hold40.0%
- Sell20.0%
- Low
- $12.12
- Now
- $10.45
- High
- $16.80
NCDL earnings
Earnings per share, reported against the analyst estimate
Beat the estimate in 2 of the last 8 quarters, by 1.9% on average.
- Q3 FY24: reported $0.58 per share against an estimate of $0.5967
- Q4 FY24: reported $0.55 per share against an estimate of $0.595
- Q1 FY25: reported $0.53 per share against an estimate of $0.5746
- Q2 FY25: reported $0.46 per share against an estimate of $0.4726
- Q3 FY25: reported $0.43 per share against an estimate of $0.459
- Q4 FY25: reported $0.44 per share against an estimate of $0.4366
- Q1 FY26: reported $0.41 per share against an estimate of $0.4335
- Q2 FY26: reported $0.41 per share against an estimate of $0.3978
NCDL news
- Press releaseBusiness Wire
Full Transcript: Nuveen Churchill Direct Q2 2026 Earnings Call
- Press releaseBusiness Wire
Nuveen Churchill Direct Lending Corp. Announces Second Quarter 2026 Results
- Press releaseBusiness Wire
Nuveen Churchill Direct Lending Corp. Schedules Second Quarter 2026 Earnings Release and Conference Call
- Press releaseBusiness Wire
Nuveen Churchill Direct Lending Corp. Announces Closing of Public Offering of Additional $100.0 Million 6.650% Notes Due 2030
- Press releaseBusiness Wire
Nuveen Churchill Direct Lending Corp. Prices Public Offering of Additional $100.0 Million 6.650% Notes Due 2030
- Press releasePRNewswire
NYSE Content Update: Hinge Health Shares Up 72% One Year from its IPO
- Press releaseBusiness Wire
Nuveen Churchill Direct Lending Corp. Announces First Quarter 2026 Results
Similar companies
Companies in the same industry as Nuveen Churchill Direct Lending
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0003−16.67%
- SEIISharing Economy International$0.0004+100.00%
- NWGLCL Workshop Group$0.1522+27.90%
- TMSHTrans Global Assets$0.0002+0.00%
- AEFIAmerican EcoFuels$0.0007+0.00%
- CBDW1606$0.0002+0.00%
- FITYFifty 1 Labs$0.0001−66.67%
- PRSOPeraso$0.5914+54.13%
- SDSTStardust Power$0.02−23.66%
- SHFSSHF Holdings$0.0899−4.36%
- FRTTFort Technology$0.7121+32.63%
- CBDLCBD Life Sciences$0.0002−25.00%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.56+1.54%
- CTYCITY THERAPEUTICS$20.83−2.94%
- IAMIambic Therapeutics$16.01−2.02%
- AMROAmaero$5.68+1.25%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.28−0.10%
- TRXBTRex Bio$14.44−2.43%
- RTSNRetension Pharmaceuticals$16.18−0.92%
- PAXGUPine Tree Acquisition$9.98+0.00%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.18+3.39%
- ACCVAccelevation Holdings$12.31−1.44%
- RZAIROZE AI$10.28+1.28%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.